Kurzrock R - Search Results

1

Phase II study of alemtuzumab in chronic lymphoproliferative disorders.

Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Ferrajoli A, et al. Among authors: kurzrock r. Cancer. 2003 Aug 15;98(4):773-8. doi: 10.1002/cncr.11551. Cancer. 2003. PMID: 12910522 Free article. Clinical Trial.

2

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Estey EH, et al. Among authors: kurzrock r. Blood. 1992 Feb 15;79(4):882-7. Blood. 1992. PMID: 1346577 Free article.

3

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Among authors: kurzrock r. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

4

Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.

Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Estrov Z, et al. Among authors: kurzrock r. Blood. 1992 Apr 15;79(8):1938-45. Blood. 1992. PMID: 1373331 Free article.

5

Fludarabine therapy in macroglobulinemic lymphoma.

Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Kantarjian HM, et al. Among authors: kurzrock r. Blood. 1990 May 15;75(10):1928-31. Blood. 1990. PMID: 1692487 Free article.

6

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Talpaz M, et al. Among authors: kurzrock r. Cancer Res. 1992 Mar 1;52(5):1087-90. Cancer Res. 1992. PMID: 1737366

7

Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.

Kurzrock R, Talpaz M, Gomez JA, Estey EH, O'Brien S, Hirsch-Ginsberg C, Koller C, Freireich EJ, Gutterman JU. Kurzrock R, et al. Br J Haematol. 1991 Jul;78(3):352-8. doi: 10.1111/j.1365-2141.1991.tb04448.x. Br J Haematol. 1991. PMID: 1873220

8

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Schilling PJ, et al. Among authors: kurzrock r. Cancer. 1991 Oct 1;68(7):1536-7. doi: 10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b. Cancer. 1991. PMID: 1893353

9

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.

Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. Talpaz M, et al. Among authors: kurzrock r. Cancer. 1991 Nov 15;68(10):2125-30. doi: 10.1002/1097-0142(19911115)68:10<2125::aid-cncr2820681006>3.0.co;2-q. Cancer. 1991. PMID: 1913450 Clinical Trial.

10

Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.

Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R. Kantarjian HM, et al. Among authors: kurzrock r. Blood. 1991 Nov 1;78(9):2411-8. Blood. 1991. PMID: 1932753 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,012 results

Search Page

Filters